The hypoxia-inducible transcription factor (HIF)-1alpha inhibitor KC7F2 described in this issue of Clinical Cancer Research is the newest addition to an emerging class of antitumor agents targeting the hypoxia response. Here, we discuss the proposed mechanism of action of KC7F2 and its potential strengths and limitations in comparison with other promising HIF-1alpha inhibitors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760048 | PMC |
| http://dx.doi.org/10.1158/1078-0432.CCR-09-1650 | DOI Listing |
Publication Analysis
Top Keywords
hypoxia response
8
inhibiting hypoxia
4
response cancer
4
cancer therapy
4
therapy kid
4
kid block
4
block hypoxia-inducible
4
hypoxia-inducible transcription
4
transcription factor
4
factor hif-1alpha
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!